Department of Bioengineering, University of Illinois at Urbana-Champaign, 1102 Everitt Lab, MC 278, 1406 W. Green St, Urbana, IL, 61801, USA.
Holonyak Micro and Nanotechnology Lab, University of Illinois at Urbana-Champaign, 208 N. Wright St., Urbana, IL, 61801, USA.
Biomed Microdevices. 2020 May 18;22(2):36. doi: 10.1007/s10544-020-00492-6.
Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response, leads the U.S in both mortality rate and cost of treatment. Sepsis treatment protocols currently rely on broad and non-specific parameters like heart and respiration rate, and temperature; however, studies show that biomarkers Interlukin-6 (IL-6) and Procalcitonin (PCT) correlate to sepsis progression and response to treatment. Prior work also suggests that using multi-parameter predictive analytics with biomarkers and clinical information can inform treatment to improve outcome. A point-of-care (POC) platform that provides information for multiple biomarkers can aid in the diagnosis and prognosis of potentially septic patients. Using impedance cytometry, microbead immunoassays, and biotin-streptavidin binding, we report a microfluidic POC system that correlates microbead capture to IL-6 and PCT concentrations. A multiplexed microbead immunoassay is developed and validated for simultaneous detection of both IL-6 and PCT from human plasma samples. Using the POC platform, we quantified plasma samples containing healthy, medium (10pg/ml) and high (10pg/ml) IL-6 and PCT concentrations with various levels of significance (P < 0.05-P < 0.00001) and validated the concept of this device as a POC platform for sepsis biomarkers.
脓毒症是一种由宿主反应失调引起的危及生命的器官功能障碍，其在美国的死亡率和治疗费用均位居前列。目前，脓毒症的治疗方案依赖于心率和呼吸频率、体温等广泛而不具体的参数；然而，研究表明，白细胞介素 6（IL-6）和降钙素原（PCT）等生物标志物与脓毒症的进展和对治疗的反应相关。先前的工作还表明，使用多参数预测分析与生物标志物和临床信息相结合，可以为治疗提供信息，以改善结果。一种提供多种生物标志物信息的即时检测（POC）平台可以帮助诊断和预测可能患有脓毒症的患者。我们使用阻抗细胞术、微珠免疫分析和生物素-链霉亲和素结合，报告了一种与 IL-6 和 PCT 浓度相关的微流控 POC 系统，该系统通过微珠捕获进行。开发并验证了一种用于同时检测人血浆样本中 IL-6 和 PCT 的多重微珠免疫分析方法。使用 POC 平台，我们定量了含有健康、中（10pg/ml）和高（10pg/ml）IL-6 和 PCT 浓度的血浆样本，具有不同的显著性水平（P < 0.05-P <0.00001），并验证了该设备作为脓毒症生物标志物 POC 平台的概念。
